Voyager Therapeutics logo

Voyager TherapeuticsNASDAQ: VYGR

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

11 November 2015

Next earnings report:

28 February 2025

Last dividends:

N/A

Next dividends:

N/A
$300.44 M
-50%vs. 3y high
59%vs. sector
-80%vs. 3y high
10%vs. sector
-87%vs. 3y high
37%vs. sector
-85%vs. 3y high
36%vs. sector

Price

after hours | Sat, 23 Nov 2024 00:41:06 GMT
$5.50+$0.07(+1.29%)

Dividend

No data over the past 3 years
$24.63 M$15.46 M
$24.63 M-$9.04 M

Analysts recommendations

Institutional Ownership

VYGR Latest News

Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences
globenewswire.com06 November 2024 Sentiment: POSITIVE

LEXINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the Company will participate in multiple upcoming investor conferences:

Voyager Therapeutics Announces Third Quarter 2024 Conference Call and Webcast
globenewswire.com05 November 2024 Sentiment: POSITIVE

LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report third quarter 2024 financial and operating results after market close on Tuesday, November 12, 2024. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET.

Strength Seen in Voyager Therapeutics (VYGR): Can Its 17.5% Jump Turn into More Strength?
zacks.com07 October 2024 Sentiment: POSITIVE

Voyager Therapeutics (VYGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences
globenewswire.com29 August 2024 Sentiment: POSITIVE

LEXINGTON, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in multiple upcoming investor conferences:

Voyager Therapeutics (VYGR) Reports Q2 Loss, Tops Revenue Estimates
zacks.com06 August 2024 Sentiment: POSITIVE

Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.51 per share a year ago.

Voyager Therapeutics to Present at Multiple Virtual Investor Conferences
globenewswire.com13 June 2024 Sentiment: POSITIVE

LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in fireside chats at the TD Cowen Genetic Medicines & RNA Summit on June 20, 2024, at 1:35 p.m. ET and at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024, at 7:00 a.m. ET.

Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer
globenewswire.com13 June 2024 Sentiment: POSITIVE

LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024. Jorgensen brings to Voyager a breadth of experience spanning investment banking, public and private healthcare investing, sell-side research, and operational roles in biotech, as well as expertise in neuroscience. He most recently served as Chief Financial Officer for Vor Biopharma Inc.

Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer's Disease
globenewswire.com16 May 2024 Sentiment: POSITIVE

Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotech company focused on advancing neurogenetic medicines, announced today that the initial participants have received doses in a Phase 1a trial of VY-TAU01, an experimental anti-tau antibody designed to block the spread of pathological tau in Alzheimer's disease.

Voyager Therapeutics (VYGR) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research13 May 2024 Sentiment: POSITIVE

Voyager Therapeutics (VYGR) reported a quarterly loss of $0.20 per share, beating the Zacks Consensus Estimate of a loss of $0.44. This is a decrease from earnings of $2.94 per share in the same quarter last year.

Voyager Therapeutics: On Track To Deliver High Returns On Investment
Seeking Alpha13 March 2024 Sentiment: POSITIVE

The company's strength lies in its TRACER capsids technology that can deliver therapeutic molecules to the brain, leading to multimillion-dollar deals with pharmaceutical giants, such as Novartis. Despite the risks and uncertainties, long-term investors may be rewarded once the company's products reach clinical trial validation. Voyager's investors should expect share price volatility. Nonetheless, based on my financial valuation and the potential upsides, I consider this company as a “buy”.

  • 1(current)

What type of business is Voyager Therapeutics?

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

What sector is Voyager Therapeutics in?

Voyager Therapeutics is in the Healthcare sector

What industry is Voyager Therapeutics in?

Voyager Therapeutics is in the Biotechnology industry

What country is Voyager Therapeutics from?

Voyager Therapeutics is headquartered in United States

When did Voyager Therapeutics go public?

Voyager Therapeutics initial public offering (IPO) was on 11 November 2015

What is Voyager Therapeutics website?

https://www.voyagertherapeutics.com

Is Voyager Therapeutics in the S&P 500?

No, Voyager Therapeutics is not included in the S&P 500 index

Is Voyager Therapeutics in the NASDAQ 100?

No, Voyager Therapeutics is not included in the NASDAQ 100 index

Is Voyager Therapeutics in the Dow Jones?

No, Voyager Therapeutics is not included in the Dow Jones index

When was Voyager Therapeutics the previous earnings report?

No data

When does Voyager Therapeutics earnings report?

The next expected earnings date for Voyager Therapeutics is 28 February 2025